Background: Phase I and II studies suggest potential benefit with targeted therapy (TT) (e.g., FGFR3, ERBB2/3 and CDK4/6 inhibitors) in relevant molecular subsets of MUC. Given increasing data supporting PD-1/PD-L1 inhibitors in MUC, rationale for combinations of TT and immunotherapy (IO) is sought. TMB is a putative biomarker of IO response; we investigated differences in TMB in relevant molecular subsets of MUC. Methods: DNA was extracted from 40 microns of FFPE sections from 2024 consecutive patients with MUC. Comprehensive genomic profiling (CGP) was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 688X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. The CGP assay included base substitutions (SUB), INDELs, copy number alterations (CNA) and fusions/rearrangements. TMB was determined on 1.2 million Mb of sequenced DNA; results are reported for the overall cohort and in subsets segregated separately by presence or absence of FGFR3, ERBB2/3, PIK3CA and CDKN2A/B alteration. Results: 2024 consecutive pts (1457:567 M:F) with MUC were assessed with a median age of 67 years. Median TMB in the overall cohort was 7.2 mutations/Mb. FGFR3, ERBB2, ERBB3, PIK3CA, and CDKN2A/B alteration were identified in 23%, 14%, 4%, 19% and 37% of pts, respectively. TMB was significantly different in pts segregated based on ERBB2 alteration (P ¼ 1.8x10
Background: Phase I and II studies suggest potential benefit with targeted therapy (TT) (e.g., FGFR3, ERBB2/3 and CDK4/6 inhibitors) in relevant molecular subsets of MUC. Given increasing data supporting PD-1/PD-L1 inhibitors in MUC, rationale for combinations of TT and immunotherapy (IO) is sought. TMB is a putative biomarker of IO response; we investigated differences in TMB in relevant molecular subsets of MUC. Methods: DNA was extracted from 40 microns of FFPE sections from 2024 consecutive patients with MUC. Comprehensive genomic profiling (CGP) was performed on hybridization-captured, adaptor ligation based libraries to a mean coverage depth of 688X for up to 315 cancer-related genes plus 37 introns from 14 genes frequently rearranged in cancer. The CGP assay included base substitutions (SUB), INDELs, copy number alterations (CNA) and fusions/rearrangements. TMB was determined on 1.2 million Mb of sequenced DNA; results are reported for the overall cohort and in subsets segregated separately by presence or absence of FGFR3, ERBB2/3, PIK3CA and CDKN2A/B alteration. Results: 2024 consecutive pts (1457:567 M:F) with MUC were assessed with a median age of 67 years. Median TMB in the overall cohort was 7.2 mutations/Mb. FGFR3, ERBB2, ERBB3, PIK3CA, and CDKN2A/B alteration were identified in 23%, 14%, 4%, 19% and 37% of pts, respectively. TMB was significantly different in pts segregated based on ERBB2 alteration (P ¼ 1.8x10
) and ERBB3 mutation (P ¼ 0.01) (Table) . ERBB2 and FGFR3 genomic alterations (GAs) were significantly mutually exclusive, while FGFR3 GAs significantly co-occurred with PIK3CA and CDKN2A/B. Further differences in CGP amongst these subsets will be presented at the meeting.
Conclusions: Given the proposed correlation between TMB and IO response, these data may inform the utility of combination strategies. Specifically, given higher TMB in pts with ERBB2/ERBB3 or PIK3CA alteration, combination studies exploring IO with TT directed at these targets may be warranted. Background: The presence of tumor infiltrating lymphocytes has been associated with a higher objective response rate (ORR) to PD-1/PD-L1 blockade. Across a variety of cancers, high EMT gene expression correlates with increased T cell infiltration. The impact of these interrelated processes on outcomes with PD-1/PD-L1 blockade has not been defined. Methods: The TCGA UC cohort (n ¼ 405) was utilized to determine the relationship between EMT gene signature (sig) expression (200 genes in MSigDB) and infiltrating T cell abundance (ITA). ITA was inferred using mRNA expression of 144 T cell genes. A phase 2 trial of nivo in metastatic UC (CheckMate 275, n ¼ 212) was used to determine the impact of EMT sig (HTG EdgeSeq) and CD8 expression (IHC) on ORR, progression-free (PFS), and overall survival (OS).
Results: In the TCGA cohort, EMT sig correlated with ITA (CC ¼ 0.60, p < 2e-16). The correlation remained significant after correction for sample purity (CC ¼ 0.37, p ¼ 1e-14) and UC molecular subtype (p ¼ 1e-13). In the CheckMate 275 cohort, EMT sig correlated with CD8 expression (CC ¼ 0.29, p ¼ 2e-05). The impact of EMT sig and CD8 expression on outcomes is shown (Table) . Higher CD8 expression was associated with longer PFS (p ¼ 0.0003) and OS (p ¼ 0.01). There was a significant interaction between EMT sig and CD8 (PFS, p ¼ 0.038; OS, p ¼ 0.064); in CD8 high tumors, ORR, PFS, and OS were worse in EMT high vs EMT low .
Conclusions: While much effort has been focused on "turning cold tumors hot" as a strategy to improve the efficacy of PD-1/PD-L1 blockade, a large proportion of "hot tumors" do not respond. Among "hot" UC, EMT high tumors are associated with a lower ORR to nivo and shorter PFS and OS. These findings substantiate EMT as a potential mechanism of immune escape and raise the possibility of co-targeting EMT and PD-1/ PD-L1 in "hot" UC. 
